2026-06-14T06:44:36Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/163962024-09-27T10:02:54Zcom_20.500.12105_19604com_20.500.12105_2051col_20.500.12105_19605

00925njm 22002777a 4500 dc Hill, Richard author Madureira, Patricia A author Ferreira, Bibiana author Baptista, Inês author Machado, Susana author Colaҫo, Laura author Dos Santos, Marta author Liu, Ningshu author Dopazo, Ana author Ugurel, Selma author Adrienn, Angyal author Kiss-Toth, Endre author Isbilen, Murat author Gure, Ali O author Link, Wolfgang author 2023-07-19 Nat Commun. 2023 Jul 19;14(1):4341. 10.1038/s41467-023-40050-1 2041-1723 Nature communications 37468494 http://hdl.handle.net/20.500.12105/16396 Retraction Note: TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT.